Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lysine hydrochloride + arginine hydrochloride
- Development stage
- Approved
- Lead developer
- Advanced Accelerator Applications
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
F-1520 is an intravenous amino acid solution containing L-lysine hydrochloride and L-arginine hydrochloride, developed by FUJIFILM Toyama Chemical (formerly FUJIFILM RI Pharma) in collaboration with Advanced Accelerator Applications (a Novartis company). It is specifically indicated as a renal protectant for use during peptide receptor radionuclide therapy (PRRT) with somatostatin analogs, such as lutetium (177Lu) oxodotreotide (F-1515). The administration of F-1520 aims to reduce the radiation dose to the kidneys by competitively inhibiting the renal tubular reabsorption of the radiolabeled peptide. By saturating the transport mechanisms in the proximal tubules, F-1520 mitigates the risk of radiation-induced nephrotoxicity in patients with somatostatin receptor-positive neuroendocrine tumors (NETs).
- Brand names
- LysaKare
- Other names
- L-lysine hydrochloride + L-arginine hydrochloridelysine + arginine
02
Targets
LRP2 (Low-density lipoprotein receptor-related protein 2)CUBN (Cubilin (intrinsic factor-vitamin B12 receptor))
Beyond the preview
Go deeper on lysine hydrochloride + arginine hydrochloride.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lysine hydrochloride + arginine hydrochloride.